– USA, CT – Saghmos Therapeutics, Inc., a privately held biopharmaceutical company, developing the cardiorenal metabolic modulator ST-62516, today announced the appointment of Fred Hassan as Chairman of its Board of Directors.
About Fred Hassan
Mr. Hassan has served as CEO and/or Chairman or Board member of global pharmaceutical companies, leading investment firms, and pharmaceutical industry organizations.
Fred Hassan is Chairman of Caret Group, and a Director at Warburg Pincus, a private equity firm. He is currently a Board member of Precigen, BridgeBio, and Cocrystal, and was on the board of Prometheus Biosciences before its acquisition by Merck in June 2023. Previously, he was also on the Board of Directors of Amgen and Time Warner, until its acquisition by AT&T, and was Chairman of the Boards of Avon Products and Bausch & Lomb.
Fred Hassan is the former Chairman of the Board and CEO of Schering-Plough Corporation before its acquisition by Merck. Previously, he was Chairman and CEO of Pharmacia Corporation before its acquisition by Pfizer. Prior to that, Mr. Hassan was EVP of Wyeth, with responsibility for its pharmaceutical and medical products business. He also headed the US pharmaceuticals business at Sandoz Pharmaceuticals. Other leadership roles include chairmanship of the Pharmaceutical Research and Manufacturers of America and the International Federation of Pharmaceutical Manufacturers Associations.
Mr. Hassan received a BS degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an MBA from Harvard Business School.
About Saghmos Therapeutics
Saghmos Therapeutics is developing ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI. This is an area of high unmet need. Patients with pre-existing Chronic Kidney Disease and comorbidities such as diabetes and heart disease are at high risk of complications, including heart failure and progression of kidney disease, leading to prolonged hospitalization and need for dialysis. There are no approved pharmacologic agents to prevent or treat the problem.
Saghmos Therapeutics has an issued US patent (Patent number 11,123,345) for the prevention and treatment of acute kidney injury after contrast procedures. The patent provides exclusivity through 2037. International patents are pending.
For more information: http://saghmos.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.